Mylan NV (NASDAQ:MYL) – Equities researchers at Svb Leerink lifted their FY2019 EPS estimates for Mylan in a report released on Tuesday, November 5th. Svb Leerink analyst A. Fadia now anticipates that the company will post earnings of $4.32 per share for the year, up from their prior estimate of $4.22. Svb Leerink also issued estimates for Mylan’s Q4 2019 earnings at $1.30 EPS, FY2020 earnings at $4.62 EPS, FY2021 earnings at $5.04 EPS, FY2022 earnings at $5.64 EPS and FY2023 earnings at $6.45 EPS.
Several other research analysts have also recently weighed in on the stock. TheStreet cut shares of Mylan from a “c-” rating to a “d+” rating in a research report on Friday, August 2nd. Mizuho boosted their price objective on shares of Mylan from $25.00 to $27.00 and gave the stock a “neutral” rating in a research report on Tuesday, July 30th. ValuEngine upgraded shares of Mylan from a “strong sell” rating to a “sell” rating in a research report on Wednesday, October 2nd. Cfra cut shares of Mylan from a “hold” rating to a “sell” rating in a research report on Tuesday. Finally, Wolfe Research initiated coverage on shares of Mylan in a research report on Friday, July 19th. They issued an “outperform” rating and a $27.00 price objective for the company. Three analysts have rated the stock with a sell rating, six have given a hold rating and eleven have assigned a buy rating to the company’s stock. The company has a consensus rating of “Hold” and a consensus target price of $27.97.
Mylan (NASDAQ:MYL) last posted its quarterly earnings data on Tuesday, November 5th. The company reported $1.17 earnings per share for the quarter, topping the consensus estimate of $1.14 by $0.03. Mylan had a net margin of 0.42% and a return on equity of 18.80%. The firm had revenue of $2.96 billion during the quarter, compared to analysts’ expectations of $3.01 billion. During the same quarter in the previous year, the company posted $1.25 EPS. Mylan’s revenue was up 3.5% on a year-over-year basis.
In other news, Director Melina E. Higgins purchased 20,000 shares of the firm’s stock in a transaction dated Thursday, August 15th. The stock was bought at an average price of $17.68 per share, with a total value of $353,600.00. Following the acquisition, the director now directly owns 33,120 shares of the company’s stock, valued at $585,561.60. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Sjoerd S. Vollebregt purchased 10,000 shares of the firm’s stock in a transaction dated Tuesday, August 13th. The stock was purchased at an average cost of $19.11 per share, with a total value of $191,100.00. Following the acquisition, the director now directly owns 18,258 shares in the company, valued at $348,910.38. The disclosure for this purchase can be found here. Insiders own 0.81% of the company’s stock.
Several hedge funds have recently made changes to their positions in the company. State of Michigan Retirement System grew its holdings in shares of Mylan by 0.5% in the 3rd quarter. State of Michigan Retirement System now owns 124,009 shares of the company’s stock valued at $2,453,000 after buying an additional 600 shares during the period. Hartford Investment Management Co. grew its holdings in shares of Mylan by 0.6% in the 3rd quarter. Hartford Investment Management Co. now owns 103,123 shares of the company’s stock valued at $2,040,000 after buying an additional 640 shares during the period. Eaton Vance Management grew its holdings in shares of Mylan by 7.1% in the 2nd quarter. Eaton Vance Management now owns 10,164 shares of the company’s stock valued at $194,000 after buying an additional 677 shares during the period. Rockefeller Capital Management L.P. grew its holdings in shares of Mylan by 22.5% in the 2nd quarter. Rockefeller Capital Management L.P. now owns 3,755 shares of the company’s stock valued at $71,000 after buying an additional 689 shares during the period. Finally, Cumberland Advisors Inc. grew its holdings in shares of Mylan by 2.1% in the 3rd quarter. Cumberland Advisors Inc. now owns 33,730 shares of the company’s stock valued at $667,000 after buying an additional 700 shares during the period. 84.46% of the stock is owned by institutional investors.
Mylan Company Profile
Mylan N.V., together with its subsidiaries, develops, licenses, manufactures, markets, and distributes generic, branded-generic, brand-name, and over-the-counter (OTC) pharmaceutical products in North America, Europe, and internationally. It offers active pharmaceutical ingredients and finished dosage forms; and antiretroviral medicines to treat HIV/AIDS.
Further Reading: What is an inverted yield curve?
Receive News & Ratings for Mylan Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mylan and related companies with MarketBeat.com's FREE daily email newsletter.